Shipments come on the heels of a severe flu season and record deaths in children.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
(CIDRAP News) – Flu activity in many Northern Hemisphere countries continued its late-season rise last week, with areas such as the United States, Canada, and Europe reporting steady increases.
Though flu activity overall is low, notable increases are occurring in North America, western Europe, and northern China, the World Health Organization (WHO) said today.
Feb 2, 2012
(CIDRAP News) – An autopsy study involving influenza B infections revealed how histologically similar the disease is to fatal influenza A and how quickly it can kill, challenging the notion that it is milder than influenza A.
The investigators, from the US Centers for Disease Control and Prevention (CDC), also found a high level of cardiac injury with fatal influenza B infections, especially in younger patients.
(CIDRAP News) – Flu activity in the United States and Europe showed more signs of picking up last week, with labs in both parts of the world finding higher percentages of positives in tests of respiratory samples, according to new surveillance reports today.
Jan 20, 2012
(CIDRAP News) – A lengthy new analysis of unpublished clinical trial data is renewing questions about the effectiveness of the influenza drug oseltamivir (Tamiflu), saying that although the drug shortens flu symptoms by about a day, there is no evidence that it reduces hospital admissions.
